MF5

MF5 is an estrogen receptor β-selective formula that prevents breast and uterine cancer.

VG3

VG3 an estrogen receptor β-selective agonist formula designed to treat menopausal vaginal dryness.

WL2

WL2 is an estrogen receptor α-tissue selective modulator resulting in weight loss and reversal of fat redistribution without the increased risk of breast and uterine cancer as well as clotting events.

IATERRP9

IATERRP9 is a nuclear receptor reprogramming drug designed to make MHT safer for long-term to treat protracted menopausal symptoms and primary prevention of chronic diseases, such as heart disease, osteoporosis and diabetes.

Clinical Trials

Iaterion is developing and testing a growing list of innovative biopharmaceuticals for multiple indications driven by hormonal, immune or cell metabolism pathologies. It is a confirmation of the company’s passion and commitment to patients with unmet medical needs.

Our drugs are in pre-clinical development.

Registries

We believe ongoing contact with patients is critical when trying to understand how our therapies work, as well as to continue monitoring their safety. This is far more crucial at this time in the world when travel is difficult. 

In an effort to transform medicine during the COVID-19 pandemic, we plan to open Clinical Registries where you and your physician can continue to update your outcomes, as well as voice your concerns. We will immediately inform you of any safety alerts. We will also periodically update results.

The registries are specific for each drug. In order to participate it requires signing an Informed Consent. All the data is encrypted and saved on Iaterion’s private secure server.